KFKenji Furuno

Kenji Furuno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenji Furuno has a total of 336 co-authors. Here are the top co-authors by number of shared publications:

  • Toshiro Hara

    Kawasaki Disease Center, Fukuoka Children's Hospital, Fukuoka, Japan

    11 shared publications
  • Hidetoshi Takada

    Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    6 shared publications
  • Ken Yamamoto

    Division of Molecular Population Genetics, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan

    5 shared publications
  • Kenichiro Yamamura

    Department of Cardiology and Intensive Care, Fukuoka Children's Hospital, 5-1-1, Kashiiteriha, Higashi-ku, Fukuoka, 813-0017, Japan

    5 shared publications
  • Yumi Mizuno

    Kawasaki Disease Center, Fukuoka Children's Hospital, 5-1-1, Kashiiteriha, Higashi-ku, Fukuoka, 813-0017, Japan

    5 shared publications
  • Masaru Miura

    Cardiology Tokyo Metropolitan Children's Medical Center Tokyo Japan

    4 shared publications

Latest Publications

  • Open Access

    Outcomes and Regional Care Patterns of Critically Ill Pediatric Emergency Patients: A Population‐Based Registry Study

    by Noriyuki Kaku, Kanako Higashi, Go Kawano, Masashi Kobayashi, Jun Muneuchi, Shinichi Morimoto, Kenji Furuno, Junpei Mukai, Jun Kono, Wakato Matsuoka, et al.

    Background: Clarifying clinical features of critically ill pediatric patients is essential for optimizing the regional emergency care system. However, the relationships between hospital case volume, interhospital transfer, and outcomes, including causes of death, remain unclear. Methods: An observational study was conducted using prospectively collected data on critically ill patients aged 15 years or younger. Patients enrolled in this study were those who met the criteria for emergency and critical care unit management in Fukuoka Prefecture, Japan, from June 2014 to May 2019. Data on etiologic categories, outcomes, interhospital transfer, and use of intensive care interventions were collected. Hospitals were classified according to patient volume (high‐volume: ≥ 100 and low‐volume: < 100 patients during the observation period). Results: Among 3124 patients, 891 (28.5%) were infants (< 1 year). The annual incidence was 0.85 per 1000 children. Endogenous, exogenous, and “undetermined” etiologies accounted for 2481 (79.4%), 495 (15.8%), and 148 (4.7%) patients, respectively. Of 327 deaths (10.5%), 157 (48.0%) occurred in infants, and 89 (56.7%) of infant deaths were classified as “undetermined”. In‐hospital mortality among admitted patients was higher in low‐volume hospitals (8.7% vs. 5.3%, p < 0.01), as was the proportion of “undetermined” deaths (49.5% vs. 28.8%, p < 0.01). Transferred patients had higher ICU admission rates (62.5% vs. 52.6%, p < 0.01), without higher mortality among admitted patients. Conclusions: Critically ill infants had high mortality, and many deaths remained undetermined. These findings highlight the need to strengthen regional transport systems and postmortem evaluation in pediatric emergency care.

  • A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysms

    by Kenji Furuno, Eisuke Suganuma, Hiroshi Masuda, Zenpei Kano, Jumpei Saito, Kensuke Shoji, Ken‐Ichi Imadome, Shoko Imai, Shinobu Kobayashi, Chisato Shimizu, et al.

    Background: In the United States, a phase I/IIa dose‐escalation study of atorvastatin in Kawasaki disease (KD) patients with coronary artery aneurysms (CAAs) demonstrated the safety and pharmacokinetics (PK) of atorvastatin. However, the tolerability and PK of atorvastatin in Japanese KD patients with CAAs remain unknown. Methods: This multicenter, single‐arm, open‐label, phase I/IIa study of atorvastatin in acute KD patients with CAAs in Japan recruited patients for a 3 + 3 dose‐escalation study of a 6‐week course of atorvastatin (0.125–0.5 mg/kg/day). The primary outcome was the safety of atorvastatin. The secondary outcomes were the PK of atorvastatin, biomarkers of inflammation, and echocardiographic assessment of CAAs. Results: We enrolled nine KD patients in this study. No dose‐limiting toxicity was observed. Therefore, we determined the maximum tolerated dose was 0.5 mg/kg/day. Although there were no serious adverse drug reactions, two participants showed minor elevations in aspartate or alanine aminotransferase that recovered spontaneously without discontinuation of atorvastatin. The Z‐scores of each coronary artery decreased from baseline to the 6‐week visit except for one lesion. The serum concentration of atorvastatin was similar to those reported in PK studies of atorvastatin conducted in children with KD in the United States between the ages of 2 and 17 years. No significant differences in estimated PK parameters were observed in each dose group compared to previous studies. Conclusions: We found that atorvastatin was safe and a dose up to 0.5 mg/kg/day for 6 weeks was well‐tolerated in Japanese children with acute KD and CAAs.


  • Open Access

    Respiratory viral infections and Kawasaki disease: A molecular epidemiological analysis

    by Kentaro Marutani, Kenji Murata, Yumi Mizuno, Sagano Onoyama, Takayuki Hoshina, Kenichiro Yamamura, Kenji Furuno, Yasunari Sakai, Junji Kishimoto, Koichi Kusuhura, et al.


  • Catheter-associated urinary tract infection and urinary tract abnormalities in young children: A retrospective study

    by Hiroyuki Oikawa, Yuya Morooka, Munehiro Furuichi, Masayoshi Shinjoh, Shotaro Nozaki, Emiri Nishi, Mizuki Yaginuma, Tomohiro Inoguchi, Kentaro Tomita, Kenji Furuno, et al.


  • A predictive score for detecting vesicoureteral reflux in children with their first Escherichia coli‐induced urinary tract infection

    by Mari Kurokawa, Kenji Murata, Takayuki Hoshina, Kenji Furuno, Yoshitsugu Kaku, Junji Kishimoto, Shouichi Ohga

    In children with a first Escherichia coli-induced febrile urinary tract infection (fUTI), routine voiding cytourethrography (VCUG) is not recommended for detecting vesicoureteral reflux (VUR). Meanwhile, the sensitivity of renal and bladder ultrasound (RBUS) for detecting VUR is insufficient. Aiming to implement VCUG properly for children with a first E. coli-induced fUTI, we attempted to construct a predictive scoring system for the early screening of VUR. This study enrolled patients aged <2 years of age hospitalized for their first E. coli-induced fUTI during the period when VCUG was implemented for all patients (2007-14, non-selective group [n = 111]) and only for those with VUR-suspected RBUS findings, bacteremia or acute focal bacterial nephritis (2016-19, selective group [n = 102]). We evaluated the accuracy of the current criteria and the VUR predictive score constructed using data from the non-selective group. In the non-selective group, 32 patients had VUR (29%). In the selective group, 20 of 45 VCUG-tested patients had VUR (44%). Among 57 patients not undergoing VCUG in the selective group, 8 had a recurrence of fUTI, 3 of whom were diagnosed with VUR. In the non-selective group, 9 patients with VUR did not fulfill the current criteria and the VUR predictive score consisting of young age, female sex, prolonged fever, hypoproteinemia, hyponatremia and hyperglycemia, showed higher sensitivity, specificity than the current criteria. The current imaging/bacteriological criteria were ineffective in screening for VUR in patients with their first E. coli-induced fUTI. The VUR predictive score can be an accurate indicator for implementing VCUG.


  • Open Access

    Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation

    by Akiko Kamori, Yuya Morooka, Kenichiro Yamamura, Pin Fee Chong, Noriko Kuga, Yasushi Takahata, Koichi Sagawa, Kenji Furuno

    Respiratory syncytial virus (RSV) infection is an important cause of hospitalization in infants and young children. Monthly administration of palivizumab during the RSV season is effective in preventing severe infections in children with comorbidities. However, determining the onset of the RSV season for starting palivizumab is often challenging. The present study aimed to evaluate the ideal timing to start palivizumab and its effect on hospitalization in the real world. We performed a retrospective, observational study to identify the relationship between the timing of the first dose of palivizumab administration and RSV-related hospitalization. Medical records from 2015 to 2019 were reviewed. We included patients who had indications for palivizumab as of July 1 in each year. We counted the proportion of children receiving palivizumab and the number of RSV infection-related hospitalizations each month. We also evaluated the differences in background and underlying disease between children with and without hospitalization. A total of 498 patients were included, and 105 (21.0%) completed the first dose in July when the RSV season usually begins in Japan. Twenty-three (4.6%) patients were hospitalized for RSV infection during the observation period, with 13 (56.5%) hospitalizations before their first dose of palivizumab. The remaining 10 patients were hospitalized after receiving 1 or more doses of palivizumab. Children living with siblings and children with cyanosis originating from congenital heart disease had a higher risk of RSV with odds ratios of 5.1 (95% confidence interval 1.48-17.6, P < .01) and 3.3 (95% confidence interval 1.33-7.94, P < .01), respectively. Delays in administering palivizumab at the beginning of the season increases the rate of RSV infection-related hospitalization. To maximize prophylactic effectiveness, administering the first dose as early as possible in the RSV season is crucial, with priority for cyanotic children or those with siblings.


  • Open Access

    Kawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan

    by Kenji Murata, Sagano Onoyama, Kenichiro Yamamura, Yumi Mizuno, Kenji Furuno, Keita Matsubara, Ken Hatae, Kiminori Masuda, Yuichi Nomura, Takuro Ohno, et al.

    The causal effects of vaccines on Kawasaki disease (KD) remain elusive. We aimed to examine the association between vaccines administered during infancy and the development of KD in Japan. We conducted a multicenter prospective case-control study using questionnaires and compared the vaccination status of infants (age: 6 weeks to 9 months) who developed KD (KD group; n = 102) and those who did not develop KD (non-KD group; n = 139). Next, we performed a case-crossover study of 98 cases in the KD group and compared the status of vaccinations between the case and control periods. We also compared the incidence of KD in children for each 5-year period before and after the addition of new vaccines (2012–2013) using data from the Nationwide Survey of KD. In the case-control study, the vaccination status of the KD and control groups did not differ to a statistically significant extent. Multivariable analysis of the vaccination status and patient backgrounds showed no significant association between vaccination and KD development. In the case-crossover study, the status of vaccinations during the case and control periods did not differ to a statistically significant extent. In the analysis of data from the Nationwide Survey of KD, the incidence of KD in children of ages subject to frequent vaccination showed no significant increases in the latter five years, 2014–2018. Based on these prospective analyses, we confirmed that vaccination in early infancy did not affect the risk of KD.


  • Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin

    by Ryohei Matsuoka, Kenji Furuno, Etsuro Nanishi, Sagano Onoyama, Hazumu Nagata, Kenichiro Yamamura, Yuichiro Sugitani, Ayako Kuraoka, Yumi Mizuno, Koichi Sagawa, et al.